<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297180</url>
  </required_header>
  <id_info>
    <org_study_id>KGO105858</org_study_id>
    <nct_id>NCT00297180</nct_id>
  </id_info>
  <brief_title>Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see&#xD;
      whether enough calories from glucose are excreted in the urine to cause weight loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in body weight from baseline to Week 12.</measure>
    <time_frame>from baseline to Week 12.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of GW869682 at the Week 2 and Week 11.</measure>
    <time_frame>at the Week 2 and Week 11</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">136</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW869682</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Have a BMI within range 30.0 to 40.0kg/m2, inclusive.&#xD;
&#xD;
          -  Females who meet above criteria must be physiologically incapable of becoming pregnant&#xD;
             (ie., surgically sterilized, or post-menopausal per protocol definition).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of eating disorders.&#xD;
&#xD;
          -  Recent history of weight loss or gain.&#xD;
&#xD;
          -  Had gastrointestinal surgery for treatment of obesity.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus.&#xD;
&#xD;
          -  Have a positive urine drug screen.&#xD;
&#xD;
          -  Have liver disease.&#xD;
&#xD;
          -  Have hepatitis B, hepatitis C, or HIV antibodies.&#xD;
&#xD;
          -  Have a thyroid disorder that is not under control with medication.&#xD;
&#xD;
          -  Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or&#xD;
             cancer).&#xD;
&#xD;
          -  Are unable to participate in an exercise program.&#xD;
&#xD;
          -  Have used weight loss drugs within 3 months before the start of the study.&#xD;
&#xD;
          -  Are currently using warfarin, digoxin, oral anti-coagulants (other than aspirin and&#xD;
             non-steroidal anti-inflammatory drugs), oral or injectable corticosteroids (inhaled &amp;&#xD;
             intranasal corticosteroids are permitted), or antiretroviral medications.&#xD;
&#xD;
          -  Used of any investigational drug or device during the study or within 30 days prior to&#xD;
             1st dosing of study medication.&#xD;
&#xD;
          -  High or low blood pressure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>February 24, 2006</study_first_submitted>
  <study_first_submitted_qc>February 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2006</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hunger</keyword>
  <keyword>obesity</keyword>
  <keyword>sodium-dependent glucose transporter</keyword>
  <keyword>GW869682</keyword>
  <keyword>body composition</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 8, 2017</submitted>
    <submission_canceled>August 15, 2018</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

